**All Interactions with Didanosine (Videx)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Allopurinol[286](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#286),[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Zyloprim) | 300 mg QD x 7 days | 400 mg (buffered formulation) x 1 dose | Not studied | Didanosine AUC: increased 113-122%; Cmax: increased 69-116% | Increased didanosine effects (pancreatitis, neuropathy) | Inhibition of presystemic metabolism by allopurinol | Consider reducing didanosine dose by 50% |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#60)  (APV)(Agenerase) | - | - | May decrease amprenavir bioavailability | - | Decreased amprenavir effects | Decreased amprenavir absorption | Separate didanosine and amprenavir doses by at least 1 hour |
| Amprenavir[117](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#117)  (APV)(Agenerase) | 600 mg BID on days 1-4 and 15-18 | 2-200 mg (tablets) QD | No significant change | Not studied | - | - | No dose adjustment necessary |
| Amprenavir[117](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#117)  (APV)(Agenerase) | 600 mg BID on days 1-4 and 15-18 | 400 mg (enteric coated capsules) QD | No significant change | Not studied | - | - | No dose adjustment necessary |
| Amprenavir[127](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#127)  (APV)(Agenerase) | 600 mg BID x 4 days | 400 mg QD (buffered and enteric coated) x 4 days | No significant effect (with either didanosine formulation) | Not studied | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Atazanavir[152](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#152),  (ATV)(Reyataz) | 300 mg with ritonavir 100 mg QD | 400 mg (enteric coated capsule) QD with food | Atazanavir AUC: no significant change; Cmax: no significant change; Ritonavir AUC: no significant change; Cmax: no significant change | Didanosine AUC: decreased 34%; Cmax: decreased 38%; Cmin: increased 25% | Decreased didanosine effects | Reduced didanosine absorption due to presence of food | Administer didanosine EC and atazanavir at different times |
| Atazanavir[124](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#124)  (ATV)(Reyataz) | 400 mg QD with food | 250 mg EC x 1 dose | Atazanavir AUC: decreased 26%; Cmax: decreased 24% | Didanosine AUC: no significant change (AUC comparable to that of didanosine 400 mg QD without tenofovir) | - | - | No dose adjustment necessary |
| Atazanavir[152](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#152),  (ATV)(Reyataz) | 400 mg QD with food | 400 mg (enteric coated capsule) QD with food | No significant change | Didanosine AUC: decreased 34%; Cmax: decreased 36% | Decreased didanosine effects | Reduced didanosine absorption due to presence of food | Administer didanosine EC and atazanavir at different times |
| Atazanavir  (ATV)(Reyataz) | 400 mg QD x 1 (given 1 hour after stavudine and didanosine) | 200 mg (buffered tabs) x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Atazanavir[122](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#122)  (ATV)(Reyataz) | 400 mg x 1 dose | Also dosed with stavudine | Atazanavir Cmax: decreased 89%; AUC: decreased 87% | Not studied | Decreased atazanavir effects | - | Dose adjustment not established |
| Atazanavir  (ATV)(Reyataz) | 400 mg x 1 dose (given simultaneously with stavudine and didanosine) | 200 mg (buffered tabs) x 1 dose | Atazanavir AUC: decreased 87%; Cmin: decreased 84%; Cmax: decreased 89% | No significant change | Decreased atazanavir effects | Altered gastric pH decreasing atazanavir absorption | Administer didanosine tablets on an empty stomach and 2 hours before or 1 hour after food or atazanavir |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Buprenorphine[441](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#441)  (Suboxone)(Buprenex) | 16 mg QD | 400 mg QD | No significant change | - | - | - | No dose adjustment necessary |
| Cidofovir[371](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#371)  (Vistide) | 3 mg/kg IV (with probenecid) on days 1 and 8 | 200 mg (buffered formulation) BID on days 2-8 | No significant change | Didanosine AUC: increased 60% | Increased didanosine effects | Possible inhibition of renal tubular secretion by probenecid or cidofovir | Dose adjustment not established |
| Ciprofloxacin[326](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#326),[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Cipro) | 750 mg Q12H x 3 days | 200 mg (buffered formulation) Q12H x 3 days | Ciprofloxacin AUC: decreased 26% when ciprofloxacin is dosed 2 hours before or 6 hours after didanosine tablets. Ciprofloxacin AUC: decreased 15-fold (with simultaneous didanosine dosing) | Didanosine AUC: decreased 16%; Cmax: decreased 28% | Decreased ciprofloxacin effects | Chelation and adsorption of ciprofloxacin by divalent/trivalent cations contained in didanosine buffer | Consider didanosine EC or administer didanosine tablets/suspension 6 hours prior to or 2 hours after ciprofloxacin administration |
| Ciprofloxacin[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Cipro) | 750 mg x 1 dose | 400 mg (enteric coated capsule) x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Dapsone[327](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#327),[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (others)(Avlosulfon) | 100 mg x 1 dose | 200 mg (buffered formulation) Q12H x 14 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| Delavirdine[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (DLV)(Rescriptor) | - | - | Delavirdine AUC: decreased 20% | Not studied | Decreased delavirdine effects | - | Consider didanosine EC or administer delavirdine at least 1 hour prior to didanosine tablets/suspension |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Delavirdine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19),[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#88)  (DLV)(Rescriptor) | 400 mg TID x 28 days | 125 or 250 mg BID x 28 days | Delavirdine AUC: decreased 19%; Cmax: decreased 32% | Didanosine AUC: decreased 21%; Cmax: decreased 20% | - | Decreased didanosine and delavirdine absorption | Separate didanosine and delavirdine doses by at least 1 hour |
| Delavirdine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (DLV)(Rescriptor) | 400 mg x 1 dose | 125 or 200 mg (buffered formulation) Q12H | Delavirdine AUC: decreased 32%; Cmax: decreased 53% | Not studied | - | - | Dose adjustment not established |
| Delavirdine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (DLV)(Rescriptor) | 400 mg x 1 dose (administered 1 hr before didanosine) | 125 or 200 mg (buffered formulation) Q12H | Delavirdine AUC: increased 20%; Cmax: increased 18% | Not studied | - | - | No dose adjustment necessary |
| Efavirenz[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#143)  (EFV)(Sustiva) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients |
| Etravirine[405](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#405)  (ETR)(Intelence) | - | 400 mg QD | Etravirine Cmax: increased 16% | No significant change | - | - | No dose adjsutment |
| Food[228](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#228) | High-fat meal, light meal, yogurt or apple sauce | 400 mg (enteric coated capsule) x 1 dose | - | Didanosine AUC(with high-fat meal): decreased 19%; AUC(with light meal): decreased 27%; AUC(with yogurt): decreased 20%; AUC(with applesauce): decreased 18%; AUC(1 hour before meal): decreased 24%; AUC (2 hours after meal): no significant change | Decreased didanosine EC effects(reduction in bioavailability by 20-25% when given with any food) | Possible increase in gastric acidity affecting didanosine EC bioavailability | Administer didanosine EC at least 1 hour prior to or 2 hours after any food |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ganciclovir[233](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#233)  (Cytovene) | 1000 mg PO Q8H | buffered formulation | Ganciclovir AUC: increased 115%; Cmax: incrased 116% (when separated by 2 hours); Ganciclovir AUC: increased 107%; Cmax: increased 108% (when taken simultaneously) | Not studied | Increased ganciclovir effects | - | No dose adjustment necessary |
| Ganciclovir[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Cytovene) | 1000 mg PO Q8H | 200 mg (buffered formulation) Q12H | Ganciclovir AUC: decreased 21% | Didanosine AUC: increased 111% | Decreased ganciclovir effects; increased didanosine effects | Decreased oral ganciclovir absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension | Consider didanosine EC or do not give didanosine tablets/suspension concurrently or within 2 hours of oral ganciclovir administration |
| Indinavir[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19),[83](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#83)  (IDV)(Crixivan) | - | Buffered formulation | Indinavir AUC: decreased 84% | Not studied | Decreased indinavir effects | Decreased indinavir absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension | Consider didanosine EC or administer indinavir at least 1 hour prior to didanosine tablets/suspension |
| Indinavir[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (IDV)(Crixivan) | 800 mg x 1 dose | 400 mg (enteric coated capsule) x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Indinavir[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (IDV)(Crixivan) | 800 mg x 1 dose | 200 mg (buffered formulation) x 1 dose | Not studied | No significant change | - | - | No dose adjustment necessary |
| Indinavir[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (IDV)(Crixivan) | 800 mg x 1 dose (administered 1 hour before didanosine) | 200 mg (buffered formulation) x 1 dose | Not studied | Didanosine AUC: decreased 17%; Cmax: no significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#16),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19),[20](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#20)  (IDV)(Crixivan) | - | Buffered formulation | Indinavir AUC: decreased 84% | Not studied | Decreased indinavir effects | Decreased indinavir absorption | Take drugs at least one hour apart  *Alternative Agents*:  **Didanosine enteric coated** |
| Itraconazole[280](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#280),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Sporanox)(Sporanox) | 200 mg (capsule) x 1 dose | 300 mg (buffered formulation) x 1 dose | Itraconaxole Cmax: undetectable | Not studied | Decreased itraconazole effects | Decreased itraconazole absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension | Administer itraconazole capsules at least 2 hours after didanosine tablets/suspension  *Alternative Agents*:  **Itraconazole solution** |
| Ketoconazole[285](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#285),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Nizoral) | 200 mg QD x 4 days | 375 mg (buffered formulation) BID x 4 days | No significant change | No significant change | Possibly decreased didanosine effects | Decreased ketoconazole absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension | Consider didanosine EC or administer ketoconazole at least 2 hours prior to didanosine tablets/suspension |
| Ketoconazole[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Nizoral) | 200 mg x 1 dose | 400 mg (enteric coated capsule) x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Loperamide[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Imodium, Imodium A-D)(Imodium) | 4 mg Q6H x 1 day | 300 mg (buffered formulation) x 1 dose | Not studied | Didanosine AUC: no significant change; Cmax: decreased 23% | - | - | No dose adjustment necessary |
| Lopinavir/ritonavir[78](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#78)  (LPV/r)(Kaletra) | - | - | - | - | - | Decreased lopinavir/ritonavir absorption | Take didanosine 1 hour before or 2 hours after lopinavir/ritonavir |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Methadone[203](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#203)  (Dolophine)(Dolophine) | - | 200 mg (buffered formulation) BID | Not studied | Didanosine AUC: decreased 57%; Cmax: decreased 44% | Decreased didanosine effects | Decreased didanosine bioavailability by methadone | Dose adjustment not established |
| Methadone[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Dolophine)(Dolophine) | stable | 200 mg (buffered formulation) x 1 dose | Not studied | Didanosine AUC: decreased 41%; Cmax: decreased 59% | Decreased didanosine effects | Decreased didanosine bioavailability by methadone | Dose adjustment not established |
| Metoclopramide[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Reglan)(Reglan) | 10 mg x 1 dose | 300 mg (buffered formulation) x 1 dose | Not studied | No significant change | - | - | No dose adjustment necessary |
| Nelfinavir[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (NFV)(Viracept) | 750 mg x 1 dose | 200 mg x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Nelfinavir[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#24)  (NFV)(Viracept) | 750 mg x 1 dose | 200 mg (buffered formulation) x 1 dose | No significant change | Not studied | - | - | No dose adjustment necessary |
| Nevirapine[95](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#95)  (NVP)(Viramune) | - | - | No significant change | Not studied | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#143)  (NVP)(Viramune) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients |
| Ranitidine[244](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#244),[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Zantac)(Zantac) | 150 mg x 1 dose | 375 mg (sachet) x 1 dose | Ranitidine AUC: decreased 16%; Cmax: no significant change | No significant change | - | Inhibition of gastric acid slightly enhancing didanosine bioavailablity by reducing acid degradation | No dose adjustment necessary |
| Ribavirin[237](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#237),[238](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#238),[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Rebetol, Virazole) | 600 mg QD x 8 weeks | 200 mg (tablets) BID x 12 weeks | No significant change | No significant change | Increased risk of mitochondrial toxicity | Ribavirin has been shown in vitro to increase intracellular triphosphate levels of didanosine. | Information from a case series suggests that combining didanosine and ribavirin increases mitochondrial toxicity by five fold. Avoid combination if possible. Monitor closely and discontinue if signs of mitochondrial toxicity develop. |
| Rifabutin[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (Mycobutin)(Mycobutin) | 300 mg or 600 mg QD x 12 days | 167 mg or 250 mg (buffered formulation) Q12H x 12 days | Not studied | Didanosine AUC: no significant change; Cmax: increased 17% | - | - | No dose adjustment necessary |
| Rilpivirine[567](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#567)  (RPV)(Edurant) | 150 mg QD | 400 mg delayed release cap taken 2 hours before rilpivirine | No significant change | No significant change | - | - | No dose adjustment necessary; Administer didanosine on an empty stomach and at least 2 hours before or at least 4 hours after rilpivirine (which must be administered with a meal). |
| Ritonavir[54](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#54),[55](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#55)  (RTV)(Norvir) | 600 mg BID | 200 mg (tablets) BID | Not studied | Didanosine AUC: decreased 15%; Cmax: decreased 15% | Decreased didanosine effects | Formulation incompatibility | Separate didanosine and ritonavir administration by at least 2.5 hours |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84)  (RTV)(Norvir) | 600 mg Q12H x 4 days | 200 mg (buffered formulation) Q12H x 4 days | No significant change | Didanosine AUC: no significant change; Cmax: decreased 16% | - | - | No dose adjustment necessary |
| Stavudine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (d4T)(Zerit) | 40 mg Q12H x 4 days | 100 mg (buffered formulation) x 4 days | Stavudine AUC: no significant change; Cmax: increased 17% | No significant change | - | - | No dose adjustment necessary |
| Stavudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#86),[87](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#87)  (d4T)(Zerit) | 40 mg Q12H x 9 doses | 100 mg Q12H x 9 doses | No significant change | No significant change | - | - | No dose adjustment necessary |
| Sulfamethoxazole[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84) | 1000 mg x 1 dose | 200 mg (buffered formulation) x 1 dose | No significant change | No significant change | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[143](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#143)  (TDF)(Viread) | - | - | - | - | Potential early virologic failure | - | Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients |
| Tenofovir disoproxil fumarate[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#96)  (TDF)(Viread) | 300 mg QD | 400 mg QD (enteric coated) x 7 days (given without food) | Not studied | Didanosine AUC: increased 48%; Cmax: increased 28% | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Tenofovir disoproxil fumarate[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#96)  (TDF)(Viread) | 300 mg QD | 400 mg QD (enteric coated) x 7 days (given with food) | - | - | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Tenofovir disoproxil fumarate[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#96),[102](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#102)  (TDF)(Viread) | 300 mg QD | 400 mg (enteric coated capsule) x 1 dose | No significant change | Didanosine AUC: increased 48% (fasted); Cmax: increased 48% (fasted)Didanosine AUC: increased 60% (fed); Cmax: increased 64% (fed) | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Tenofovir disoproxil fumarate[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#96)  (TDF)(Viread) | 300 mg QD | 250 mg or 400 mg (buffered formulation) QD x 7 days | No significant change | Didanosine AUC: increased 44%; Cmax: increased 28% | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Tenofovir disoproxil fumarate[97](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#97),[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#96)  (TDF)(Viread) | 300 mg QD x 7 days | 400 mg (buffered formulation) QD x 7 days | No significant change | Didanosine AUC: increased 44%; Cmax: increased 28% | Increased didanosine effects | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Tenofovir disoproxil fumarate[103](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#103)  (TDF)(Viread) | 300 mg QD x 9 days | 250 mg QD (enteric coated) x 1 (given with food, without food and staggered by 2 hours) | No significant change | Didanosine AUC: no significant change (fed); Cmax: no significant change; Didanosine AUC: no significant change (staggered); Cmax: no significant change (staggered); Didanosine AUC: no significant change (fed); Cmax: decreased 29% (fed)All values compared to 400 mg QD (enteric coated) reference dose. | - | Possible shared elimination pathway | Reduce didanosine dose to 250 mg QD when used with tenofovir |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#154)  (TPV)(Aptivus) | 1250 mg BID with 100 mg ritonavir BID x 42 doses | 125 mg BID x 43 doses | - | Didanosine AUC: no significant change; Cmax: decreased 23% | - | - | No dose adjustment necessary; separate didanosine formulations from tipranavir by 2 hours |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Didanosine** | **Effect on Drug Levels** | **Effect on Didanosine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#154)  (TPV)(Aptivus) | 250 mg BID with 200 mg ritonavir BID | 200 mg BID | - | Didanosine AUC: decreased 33%; Cmax: decreased 43% | - | - | No dose adjustment necessary; separate didanosine formulations away from tipranavir by 2 hours |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#154)  (TPV)(Aptivus) | 500 mg BID with 100 mg ritonavir BID x 27 doses | 400 mg x 1 | Tipranavir AUC: no significant change; Cmax: increased 32%; Cmin: decreased 34% | Didanosine AUC: no significant change; Cmax: decreased 20%; Cmin: no significant change | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 100 mg ritonavir BID | 200 mg BID | - | Didanosine AUC: no significant change; Cmax: decreased 24% | - | - | No dose adjustment necessary; separate didanosine formulations from tipranavir by 2 hours |
| Trimethoprim[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (Trimpex)(Trimpex) | 200 mg x 1 dose | 200 mg (buffered formulation) x 1 dose | Trimethoprim AUC: no significant change; Cmax: decreased 22% | Didanosine AUC: no significant change; Cmax: increased 17% | - | - | No dose adjustment necessary |
| Zidovudine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=17&post=4#19)  (AZT, ZDV)(Retrovir) | 200 mg Q8H x 3 days | 200 mg (buffered formulation) Q12H x 3 days | Zidovudine AUC: no significant change; Cmax: decreased 16.5% | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 16: | Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005. |
| 19: | Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003. |
| 20: | Mummaneni V, Damle B, Kaul S, Knupp CA. Lack of effect of didanosine encapsulated enteric coated beadlet formulation on the pharmacokinetics of indinavir, ketoconazole, and ciprofloxacin in healthy subjects [abstract #1629]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada. |
| 24: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 54: | Cato A, Qian J, Hsu A, et al. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:466-72. |
| 55: | Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2008. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 78: | Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005. |
| 83: | Shelton MJ, et al. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects. Animicrob Agents Chemother 2001;45:298-300. |
| 84: | Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005. |
| 86: | Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005. |
| 87: | Seifert RD, Stewart MB, Sramek JJ. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994;38:405-10. |
| 88: | Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001. |
| 95: | Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 96: | Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006. |
| 97: | Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina. |
| 102: | Kearney B, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection; 2002 November 17-21; Glasgow, United Kingdom. |
| 103: | Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract #533]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 117: | Shelton MJ, Giovanniello AG, Cloen D, et al. The effects of didanosine formulations on the pharmacokinetics of amprenavir [abstract #A-1826]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 122: | Omara E et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract #504]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California. |
| 124: | Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract #A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 127: | Shelton MJ, Giovanniello AA, Cloen D, et al. Effects of didanosine formulations on the pharmacokinetics of amprenavir. Pharmacotherapy 2003; 23: 835-42. |
| 143: | Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004. |
| 152: | Kaul S, Olszyk C, Ji P, et al. Pharmacokinetics of didanosine enteric coated capsules co-administered with atazanavir or atazanavir/ritonavir [abst. #648]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 February 22-25; Boston, Massachusetts. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 203: | Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-8. |
| 228: | Damle BD, Yan J, Behr D, et al. Effect of food on oral bioavailability of didanosine from delayed release capsules containing enteric coated beads [abstract #A-499]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |
| 233: | Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:227-34. |
| 237: | Japour AJ, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retroviral 1996;13:235-46. |
| 238: | Fleischer R, Boxwell D, Sherman KE. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and didanosine [abstract #763]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 244: | Knupp CA, et al. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992;36:2075-9. |
| 280: | May DB, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13. |
| 285: | Knupp CA, et al. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropsoitive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912-17. |
| 286: | Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine (ddI) absorption in HIV-infected patients [abstract #A-498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |
| 326: | Knupp CA, et al. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymtomatic. Biopharm Drug Dispos 1997;18:65-77. |
| 327: | Sahai J, et al. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584-7. |
| 371: | Luber A, Lalezari J, Rooney J, et al. Drug-drug interaction study with intravenous cidofovir (CDV) and either trimethoprim-sulfamethoxazole (TMP/SMX), didanosine (DDI) or fluconazole (FLU) in HIV-infected individuals. [abstract #A-1828]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 405: | Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010. |
| 441: | Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California. |
| 567: | Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011. |